Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Goel · SciRah

Researcher profile · Semantic Scholar

S. Goel

Share profile

S. Goel — researcher profile on SciRah

h-index: 35
Works: 119
Citations: 9,177

Most-cited papers

CDK4/6 inhibition triggers anti-tumor immunity
S. Goel, Molly J Decristo, April C. Watt, Haley BrinJones +16 more
2017Nature1,304 citations Open access
Semantic Scholar
Vascular normalization as an emerging strategy to enhance cancer immunotherapy
Yuhui Huang, S. Goel, Du-Da G. Dan, D. Fukumura +1 more
2013Cancer Research608 citations Open access
Semantic Scholar
Targeting cyclin-dependent kinases 4 and 6 in cancer
S. Goel, J. Bergholz, Jean J. Zhao
2022Nature Reviews. Cancer441 citations Open access
Semantic Scholar
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors
S. Goel, Qi Wang, April C. Watt, S. Tolaney +14 more
2016Cancer Cell433 citations Open access
Semantic Scholar
CDK4/6 inhibition in cancer: beyond cell cycle arrest
S. Goel, Molly J Decristo, S. McAllister, Jean J. Zhao
2018Trends in Cell Biology419 citations Open access
Semantic Scholar
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma
Jieqiong Liu, S. Liao, B. Diop-Frimpong, Wei Chen +6 more
2012Proceedings of the National Academy of Sciences of the United States of America325 citations Open access
Semantic Scholar
CDK4/6 inhibition in breast cancer: current practice and future directions
S. Pernas, S. Tolaney, E. Winer, S. Goel
2018Therapeutic Advances in Medical Oncology267 citations Open access
Semantic Scholar
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
S. Tolaney, Y. Boucher, Du-Da G. Dan, John D. Martin +14 more
2015Proceedings of the National Academy of Sciences of the United States of America246 citations Open access
Semantic Scholar
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
K. El Bairi, H. R. Haynes, E. Blackley, S. Fineberg +70 more
2021npj Breast Cancer236 citations Open access
Semantic Scholar
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
S. Tolaney, Andrew M. Wardley, S. Zambelli, J. Hilton +13 more
2020The Lancet Oncology200 citations
Semantic Scholar
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Z. Kos, Elvire Roblin, Rim S. Kim, S. Michiels +89 more
2020npj Breast Cancer185 citations Open access
Semantic Scholar
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
M. Amgad, E. Stovgaard, E. Balslev, J. Thagaard +64 more
2020npj Breast Cancer157 citations Open access
Semantic Scholar
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
D. Kodack, Euiheon Chung, H. Yamashita, J. Incio +16 more
2012Proceedings of the National Academy of Sciences of the United States of America156 citations Open access
Semantic Scholar
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt, S. Goel
2022Breast Cancer Research125 citations Open access
Semantic Scholar
Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.
E. Ager, S. V. Kozin, N. Kirkpatrick, G. Seano +12 more
2015Journal of the National Cancer Institute117 citations Open access
Semantic Scholar
Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
Jing Ni, S. Ramkissoon, Shao-Zhen Xie, S. Goel +21 more
2016Nature Medicine112 citations Open access
Semantic Scholar
An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer
Ji Li, P. Choi, C. Chaffer, Katherine M. Labella +17 more
2018eLife110 citations Open access
Semantic Scholar
Inhibition of CDK4/6 promotes CD8 T cell memory formation
Max Heckler, Lestat R. Ali, E. Clancy-Thompson, Li Qiang +20 more
2021Cancer Discovery109 citations Open access
Semantic Scholar
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.
S. Goel, N. Gupta, B. Walcott, M. Snuderl +15 more
2013Journal of the National Cancer Institute109 citations Open access
Semantic Scholar
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity
April C. Watt, P. Cejas, Molly J Decristo, O. Metzger-Filho +29 more
2020Nature Cancer94 citations Open access
Semantic Scholar
Cell Cycle-Targeting MicroRNAs as Therapeutic Tools Against Refractory Cancers
P. Hydbring, Yinan Wang, A. Fassl, Xiaoting Li +23 more
2017Cancer Cell92 citations Open access
Semantic Scholar
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
H. Bergholtz, Jodi M. Carter, A. Cesano, M. Cheang +28 more
2021Cancers81 citations Open access
Semantic Scholar
Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
G. Ferraro, D. Kodack, V. Askoxylakis, Q. Sheng +29 more
201778 citations
Semantic Scholar
Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
K. T. Bui, Melina L. Willson, S. Goel, J. Beith +1 more
2020Cochrane Database of Systematic Reviews67 citations Open access
Semantic Scholar
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
A. Garrido-Castro, S. Goel
2017Current Breast Cancer Reports67 citations Open access
Semantic Scholar
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
R. Kudo, A. Safonov, Catherine Jones, E. Moiso +24 more
2023bioRxiv65 citations Open access
Semantic Scholar
Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
Yang Zhao, K. Ting, Jia Li, V. Cogger +13 more
2017Cancer Research48 citations Open access
Semantic Scholar
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
S. Goel, Jia Liu, Hao Guo, W. Barry +13 more
2019JACC. Heart failure47 citations Open access
Semantic Scholar
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Lestat R. Ali, A. Garrido-Castro, P. Lenehan, Naima Bollenrucher +6 more
2023Journal of Experimental Medicine40 citations Open access
Semantic Scholar
Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology
S. Goel, D. Fukumura, R. Jain
2012Proceedings of the National Academy of Sciences of the United States of America37 citations Open access
Semantic Scholar
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
S. Wander, N. O'Brien, L. Litchfield, D. O'Dea +3 more
2022The Oncologist36 citations Open access
Semantic Scholar
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
L. Spring, Shealagh Clark, Tian-Yu Li, S. Goel +10 more
2021npj Breast Cancer35 citations Open access
Semantic Scholar
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
S. Goel, S. Pernas, Z. Tan-Wasielewski, W. Barry +9 more
2019Clinical Breast Cancer34 citations
Semantic Scholar
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
D. Kodack, V. Askoxylakis, G. Ferraro, Q. Sheng +29 more
2017Science Translational Medicine30 citations Open access
Semantic Scholar
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature
S. David, G. Ho, D. Day, M. Harris +7 more
2020Translational Oncology28 citations Open access
Semantic Scholar
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
M. Michaelson, J. Bellmunt, G. Hudes, S. Goel +10 more
2012Annals of Oncology27 citations Open access
Semantic Scholar
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
R. Alomran, M. White, Melissa Bruce, M. Bressel +6 more
2021BMC Cancer24 citations Open access
Semantic Scholar
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
S. Tolaney, A. Wardley, S. Zambelli, J. Hilton +11 more
2019Annals of Oncology23 citations Open access
Semantic Scholar
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
S. Goel, A. Tan, H. Rugo, P. Aftimos +6 more
2022Future Oncology20 citations Open access
Semantic Scholar
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.
S. Goel, I. Krop
2016Annals of Oncology20 citations Open access
Semantic Scholar
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
S. Tolaney, S. Goel, J. Nadal, H. Denys +6 more
2023Clinical Cancer Research19 citations Open access
Semantic Scholar
Role of oxidative stress in angiogenesis and the therapeutic potential of antioxidants in breast cancer.
B. Mdkhana, S. Goel, M. A. Saleh, R. Siddiqui +2 more
2022European Review for Medical and Pharmacological Sciences19 citations
Semantic Scholar
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer
S. Pernas, J. Guerriero, S. Naumenko, S. Goel +11 more
2022Therapeutic Advances in Medical Oncology15 citations Open access
Semantic Scholar
A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
S. Tolaney, Dan-Du G. Da, Y. Boucher, S. Goel +10 more
201213 citations
Semantic Scholar
Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC)
C. Herold, L. Trippa, Tian-Yu Li, K. Do +10 more
202012 citations
Semantic Scholar
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.
S. Goel, I. Krop
2015Journal of Clinical Oncology10 citations
Semantic Scholar
A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC).
Otto Metzger, S. Goel, W. Barry, E. Hamilton +9 more
20179 citations
Semantic Scholar
Emerging Therapies for Breast Cancer.
S. Goel, S. Chandarlapaty
2022Cold Spring Harbor Perspectives in Medicine8 citations Open access
Semantic Scholar
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
S. Goel, S. Tolaney
2019The Lancet Oncology7 citations
Semantic Scholar
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
L. Spring, S. Goel, S. Sutherland, J. Supko +6 more
2019Journal of Clinical Oncology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Tolaney×16
Invite
S. Tolaney — researcher profile on SciRah
R. Jain×10
Invite
R. Jain — researcher profile on SciRah
I. Krop×9
Invite
I. Krop — researcher profile on SciRah
E. Winer×9
Invite
E. Winer — researcher profile on SciRah

×9

Invite

Jean J. Zhao — researcher profile on SciRah

Invite

D. Fukumura — researcher profile on SciRah

April C. Watt×4

Invite

April C. Watt — researcher profile on SciRah

Invite

Yuhui Huang — researcher profile on SciRah

Du-Da G. Dan×4

Invite

Du-Da G. Dan — researcher profile on SciRah

Invite

Y. Boucher — researcher profile on SciRah

Invite

W. Barry — researcher profile on SciRah

Invite

S. Isakoff — researcher profile on SciRah